Moditen Depo (Fluphenazine Decanoate)

Fluphenazine Decanoate, the active ingredient in Moditen Depo, is a phenothiazine antipsychotic presented as an unspecified strength injectable for intravenous use. It is employed to manage schizophrenia and acute psychotic episodes in adult patients.

GNH USA supplies Moditen Depo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Fluphenazine Decanoate is used within the antipsychotic drug class to treat disorders characterized by dopamine dysregulation.

- Schizophrenia: reduces positive and negative psychotic symptoms in adult patients. - Acute psychotic episodes: helps control severe agitation, hallucinations, and delusions. - Schizoaffective disorder: manages psychotic features alongside mood symptoms.

Fluphenazine Decanoate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Sedation or drowsiness - Extrapyramidal symptoms such as rigidity or tremor - Dry mouth and reduced salivation - Constipation - Blurred vision - Weight gain

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Tardive dyskinesia - Severe hypotension or orthostatic collapse - Agranulocytosis or severe leukopenia - Seizures - Cardiac arrhythmias, including QT prolongation

Before initiating therapy with Fluphenazine Decanoate, clinicians should consider several safety measures.

- Monitor extrapyramidal symptoms: assess for rigidity, tremor, or abnormal movements regularly. - Assess cardiovascular status: watch for hypotension, especially after the first dose. - Evaluate metabolic parameters: track weight, glucose, and lipid changes. - Use caution in hepatic impairment: dose adjustments may be required. - Avoid abrupt discontinuation: taper to reduce withdrawal risk. - Store at ambient temperature: keep in original container, protect from moisture and light.

Fluphenazine Decanoate can interact with other medications, altering efficacy or safety.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines, opioids): increased sedation. - Anticholinergic agents: heightened anticholinergic burden. - QT‑prolonging drugs (e.g., certain antiarrhythmics): risk of cardiac arrhythmia. - CYP2D6 inhibitors (e.g., fluoxetine): elevated fluphenazine levels. - Lithium: enhanced neurotoxic potential.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive hypotensive effect. - Antidiabetic agents: possible alteration of glucose control. - Other antipsychotics: cumulative extrapyramidal risk.